Your session is about to expire
← Back to Search
Vasodilator
Inhaled Nitric Oxide (iNO) for Liver Transplant
Phase 2
Waitlist Available
Led By Michael A Ramsay, MD
Research Sponsored by Baylor Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Liver Transplant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).
Eligible Conditions
- Liver Transplant
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2014 Phase 2 trial • 124 Patients • NCT0095548722%
Sepsis
8%
Necrotizing enterocolitis
5%
Threshold ROP
5%
Symptomatic PDA
3%
Severe ICH
100%
80%
60%
40%
20%
0%
Study treatment Arm
Inhaled Nitric Oxide (iNO)
Placebo (Nitrogen)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Placebo and StudyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Inhaled Nitric Oxide (iNO)
2007
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
Baylor Research InstituteLead Sponsor
206 Previous Clinical Trials
203,423 Total Patients Enrolled
MallinckrodtIndustry Sponsor
201 Previous Clinical Trials
15,864 Total Patients Enrolled
Michael A Ramsay, MDPrincipal InvestigatorBaylor Health Care System
Share this study with friends
Copy Link
Messenger